472 results on '"Batra, Atul"'
Search Results
102. Development and validation of the ethical challenges in clinical situations-questionnaire (ECCS-Q) by involving health-care providers from a tertiary care health setting
103. Development and validation of the ethical challenges in clinical situations-questionnaire (ECCS-Q) by involving health-care providers from a tertiary care health setting.
104. Association of a Shortened Duration of Adjuvant Chemotherapy With Overall Survival Among Individuals With Stage III Colon Cancer
105. Utility of 18F-FDG-PET/CT in management and prognostication of treatment naïve late-stage soft tissue sarcomas
106. Four Cycles of Docetaxel-Cyclophosphamide versus Anthracycline-Taxane as Adjuvant Chemotherapy for HER2-Negative, Axillary Lymph Node Negative Breast Cancer: A Real-World Comparison of Alberta Patients Treated 2008–2012
107. Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Early Triple-Negative Breast Cancer
108. Differential effect of body mass index (BMI) on outcomes of patients treated with docetaxel in prostate cancer: An exploratory analysis.
109. Associations of education, residence, and travel distance to oncology center on survival outcomes in patients with penile cancer: A tertiary care referral center experience.
110. Abstract PS7-47: Real-world treatment patterns in older patients with stage I-III breast cancer: A population-based study
111. Abstract PD12-04: Long-term risks of cerebrovascular accidents (CVAs) in patients with breast cancer
112. Abstract PS13-29: Four cycles of docetaxel-cyclophosphamide versus anthracycline-taxane adjuvant chemotherapy in node negative, HER2-negative breast cancer: A real-world comparison
113. HER2 positivity in patients with estrogen receptor (ER) positive breast cancer: Is it really prognostic?
114. Correlation of pathological complete response with outcomes in locally advanced breast cancer treated with neoadjuvant chemotherapy: An ambispective study
115. Additional file 1 of Impact of pre-existing cardiovascular disease on treatment patterns and survival outcomes in patients with lung cancer
116. Low-Dose Abiraterone in Metastatic Prostate Cancer: Is It Practice Changing? Facts and Facets
117. Symptom burden in patients with common cancers near end-of-life and its associations with clinical characteristics: a real-world study
118. Associations of rural residence and low socioeconomic status on the risk of new onset cardiovascular disease (CVD) in cancer patients.
119. Eligibility of real-world patients with metastatic lung cancer for clinical trial participation: A population-based analysis.
120. Obesity and Its Impact on Outcomes in Patients With Stage III Colon Cancer Receiving Adjuvant Chemotherapy
121. Factors associated with the initiation of chemotherapy within 90 days of death in metastatic colorectal cancer patients: a population-based study
122. Associations between baseline symptom burden as assessed by patient-reported outcomes and overall survival of patients with metastatic cancer
123. How We Treat Genitourinary Cancers During COVID-19 Pandemic?
124. Trastuzumab Emtansine for Residual Invasive Human Epidermal Growth Receptor-2-Positive Breast Cancer
125. Real-world evidence on adjuvant chemotherapy in older adults with stage II/III colon cancer
126. Adjuvant systemic therapies for melanoma in Alberta: An early descriptive analysis of population characteristics and treatment outcomes.
127. Impact of baseline symptom burden as assessed by patient-reported outcomes (PROs) on overall survival (OS) of patients with metastatic cancer.
128. Impact of preexisting cardiovascular disease (CVD) on treatments and outcomes of patients with breast or lung cancer.
129. Use of Twitter among cancer clinicians and researchers and the associations with scientific impact of its users and followers.
130. Referral-to-treatment attrition and its impact on outcomes of patients with advanced gastroesophageal cancers.
131. Impact of Pre-Existing Cardiovascular Disease on Treatment Patterns and Survival Outcomes in Patients With Lung Cancer
132. Protecting health-care professionals and workers (other than COVID-19 management facilities) from contamination during COVID-19 pandemic (March 26, 2020 – India)
133. Has India met this enemy before? From an eternal optimist’s perspective: SARS-CoV-2
134. How I Treat Epithelial Ovarian Cancer during COVID-19 Pandemic
135. Colorectal Cancer Chemotherapy during COVID-19 Pandemic
136. Gallbladder Cancer: Adjuvant and Palliative Treatment during Covid-19 Pandemic in India
137. Management of Head-and-Neck Cancer during COVID-19 Crisis: A Medical Oncology Perspective
138. Cancer Surgery in Challenging Time of COVID-19 Pandemic – A Pragmatic Approach
139. How We Treat lung Cancer during SARS-Cov-2 (COVID-19) Pandemic in India?
140. Breast Cancer Treatment during the COVID-19 Pandemic
141. Systemic Treatment of Gastroesophageal Cancer during SARS-CoV2
142. Real-world eligibility of advanced pancreatic (APC) patients for maintenance olaparib.
143. Eligibility of real-world patients with stage II/III colorectal cancer (CRC) in adjuvant chemotherapy (AC) trials.
144. Adjuvant trastuzumab emtansine in human epidermal growth factor receptor 2-positive breast cancer: Take-home points from the KATHERINE trial
145. An unusual durable response with palbociclib plus letrozole in hormone receptor positive metastatic breast cancer after multiple lines of therapy
146. Unusual gastric metastasis in triple-negative (estrogen receptor/progesterone receptor/HER2neu negative) GATA-binding protein 3-positive breast cancer
147. Oncotype DX: Where Does It Stand in India?
148. Primary CNS Lymphoma in India: A 17-Year Experience From the All India Institute of Medical Sciences
149. Recurrent germ cell tumour presenting as fractured neck of the femur.
150. Abstract 1256: Validation of Ubiquitin specific peptidases 37 as a prognostic and diagnostic marker in osteosarcoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.